Advertisement

Journal of Neuro-Oncology

, Volume 137, Issue 2, pp 367–377 | Cite as

Is a pretreatment radiological staging system feasible for suggesting the optimal extent of resection and predicting prognosis in glioblastoma? An observational study

  • Jaume Capellades
  • Josep Puig
  • Sira Domenech
  • Teresa Pujol
  • Laura Oleaga
  • Angels Camins
  • Carles Majós
  • Rocio Diaz
  • Christian de Quintana
  • Pilar Teixidor
  • Gerard Conesa
  • Gerard Plans
  • Josep Gonzalez
  • Natalia García-Balañà
  • Jose Maria Velarde
  • Carmen BalañaEmail author
Clinical Study

Abstract

To assess the value of resection in glioblastoma based on pre-surgical tumor characteristics and a subsequent staging system. The lack of a staging system for glioblastoma hinders the analysis of treatment outcome. We classified 292 uniformly treated glioblastoma patients as stage I, II, or III based on tumor size, location, and eloquence and then analyzed the impact of the extent of resection. We classified 62% of patients as stage I, 25.3% as stage II, and 12.7% as stage III. Gross total resection (GTR) was performed mainly in stage I rather than stage II or III patients (79.2% vs. 14.6% vs. 6.3%; P < 0.001). Overall survival (OS) was 17.7, 14.6, and 10.8 months for stage I, II, and III patients, respectively (P = 0.005). Longer OS was significantly associated with greater extent of resection, younger age, KPS ≥ 70%, MGMT methylation, lower stage, and tumor ≤ 5 cm. In the subgroups of stage I (P = 0.04) and stage II (P < 0.001)—but not stage III—patients, GTR and partial resection (PR) were associated with longer OS. We constructed several multivariable models including different variables, and greater extent of resection, smaller tumor size, and MGMT methylation consistently emerged as independent markers of longer OS. This staging system provides a feasible tool for comparison of results. We confirmed the value of partial resection in stage I and II patients, in contrast to some reports suggesting that biopsy only is sufficient when gross total resection cannot be safely achieved.

Keywords

Glioblastoma Staging Extent of resection Imaging MGMT Prognosis 

Notes

Funding

This work was supported by Fundació La Marató TV3 (665/C/2013) (http://www.ccma.cat/tv3/marato/projectes-financats/2012/231/). The radiological platform is supported by the citizens’ initiative “Associacio Montgat en Acció”: G66504572.

Compliance with ethical standards

Conflict of interest

Carmen Balaña declares an advisory position for AbbVie and financial support for attending symposia of Pharmamar. The rest of authors declare they don’t have any conflict of interest.

Supplementary material

11060_2017_2726_MOESM1_ESM.docx (18 kb)
Supplementary material 1 (DOCX 18 KB)
11060_2017_2726_MOESM2_ESM.docx (16 kb)
Supplementary material 2 (DOCX 16 KB)
11060_2017_2726_MOESM3_ESM.docx (17 kb)
Supplementary material 3 (DOCX 17 KB)
11060_2017_2726_MOESM4_ESM.docx (15 kb)
Supplementary material 4 (DOCX 15 KB)
11060_2017_2726_MOESM5_ESM.docx (16 kb)
Supplementary material 5 (DOCX 15 KB)
11060_2017_2726_MOESM6_ESM.docx (15 kb)
Supplementary material 6 (DOCX 15 KB)
11060_2017_2726_MOESM7_ESM.docx (16 kb)
Supplementary material 7 (DOCX 16 KB)
11060_2017_2726_MOESM8_ESM.docx (15 kb)
Supplementary material 8 (DOCX 14 KB)
11060_2017_2726_MOESM9_ESM.docx (16 kb)
Supplementary material 9 (DOCX 15 KB)
11060_2017_2726_MOESM10_ESM.docx (14 kb)
Supplementary material 10 (DOCX 14 KB)
11060_2017_2726_MOESM11_ESM.docx (16 kb)
Supplementary material 11 (DOCX 15 KB)
11060_2017_2726_MOESM12_ESM.docx (17 kb)
Supplementary material 12 (DOCX 16 KB)

References

  1. 1.
    Stummer W, Meinel T, Ewelt C, Martus P, Jakobs O, Felsberg J, Reifenberger G (2012) Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J Neurooncol 108:89–97.  https://doi.org/10.1007/s11060-012-0798-3 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Stummer W, van den Bent MJ, Westphal M (2011) Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochirurgica 153:1211–1218.  https://doi.org/10.1007/s00701-011-1001-x CrossRefPubMedGoogle Scholar
  3. 3.
    Chaichana KL, Halthore AN, Parker SL, Olivi A, Weingart JD, Brem H, Quinones-Hinojosa A (2011) Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article. J Neurosurg 114:604–612.  https://doi.org/10.3171/2010.4.JNS091340 CrossRefPubMedGoogle Scholar
  4. 4.
    Daigle K, Fortin D, Mathieu D, Saint-Pierre AB, Pare FM, de la Sablonniere A, Goffaux P (2013) Effects of surgical resection on the evolution of quality of life in newly diagnosed patients with glioblastoma: a report on 19 patients surviving to follow-up. Curr Med Res Opin 29:1307–1313.  https://doi.org/10.1185/03007995.2013.823858 CrossRefPubMedGoogle Scholar
  5. 5.
    Chandrasoma PT, Smith MM, Apuzzo ML (1989) Stereotactic biopsy in the diagnosis of brain masses: comparison of results of biopsy and resected surgical specimen. Neurosurgery 24:160–165CrossRefGoogle Scholar
  6. 6.
    Moliterno JA, Patel TR, Piepmeier JM (2012) Neurosurgical approach. Cancer J 18:20–25.  https://doi.org/10.1097/PPO.0b013e3183243f6e300130404-201201000-00005 CrossRefPubMedGoogle Scholar
  7. 7.
    Capellades J, Teixidor P, Villalba G, Hostalot C, Plans G, Armengol R, Medrano S, Estival A, Luque R, Gonzalez S, Gil-Gil M, Villa S, Sepulveda J, Garcia-Mosquera JJ, Balana C (2017) Results of a multicenter survey showing interindividual variability among neurosurgeons when deciding on the radicality of surgical resection in glioblastoma highlight the need for more objective guidelines. Clin Transl Oncol 19:727–734.  https://doi.org/10.1007/s12094-016-1598-6 CrossRefPubMedGoogle Scholar
  8. 8.
    Sonabend AM, Zacharia BE, Cloney MB, Sonabend A, Showers C, Ebiana V, Nazarian M, Swanson KR, Baldock A, Brem H, Bruce JN, Butler W, Cahill DP, Carter B, Orringer DA, Roberts DW, Sagher O, Sanai N, Schwartz TH, Silbergeld DL, Sisti MB, Thompson RC, Waziri AE, McKhann G 2nd (2017) Defining glioblastoma resectability through the wisdom of the crowd: a proof-of-principle study. Neurosurgery 80: 590–601  https://doi.org/10.1227/NEU.0000000000001374 CrossRefPubMedGoogle Scholar
  9. 9.
    Ferroli P, Schiariti M, Finocchiaro G, Salmaggi A, Castiglione M, Acerbi F, Tringali G, Farinotti M, Broggi M, Roberto C, Maccagnano E, Broggi G (2013) Operability of glioblastomas: “sins of action” versus “sins of non-action”. Neurol Sci 34:2107–2116.  https://doi.org/10.1007/s10072-013-1345-5 CrossRefPubMedGoogle Scholar
  10. 10.
    Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, Patel AS, Rizk EB, Suki D, Sawaya R, Glantz M (2016) Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol 2:1460–1469.  https://doi.org/10.1001/jamaoncol.2016.1373 CrossRefPubMedGoogle Scholar
  11. 11.
    Trifiletti DM, Alonso C, Grover S, Fadul CE, Sheehan JP, Showalter TN (2017) Prognostic implications of extent of resection in glioblastoma: analysis from a large database. World Neurosurg.  https://doi.org/10.1016/j.wneu.2017.04.035 CrossRefPubMedGoogle Scholar
  12. 12.
    Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198CrossRefGoogle Scholar
  13. 13.
    Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, Raza SM, Pascual-Gallego M, Ibrahim A, Hernandez-Hermann M, Gomez L, Ye X, Weingart JD, Olivi A, Blakeley J, Gallia GL, Lim M, Brem H, Quinones-Hinojosa A (2014) Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 16:113–122.  https://doi.org/10.1093/neuonc/not137 CrossRefPubMedGoogle Scholar
  14. 14.
    Grabowski MM, Recinos PF, Nowacki AS, Schroeder JL, Angelov L, Barnett GH, Vogelbaum MA (2014) Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg 121:1115–1123.  https://doi.org/10.3171/2014.7.JNS132449 CrossRefPubMedGoogle Scholar
  15. 15.
    Kuhnt D, Becker A, Ganslandt O, Bauer M, Buchfelder M, Nimsky C (2011) Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance. Neuro-oncology 13:1339–1348.  https://doi.org/10.1093/neuonc/nor133 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115:3–8.  https://doi.org/10.3171/2011.2.JNS10998 CrossRefPubMedGoogle Scholar
  17. 17.
    McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, Weingart JD, Brem H, Quinones-Hinojosa AR (2009) Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 110:156–162CrossRefGoogle Scholar
  18. 18.
    Marko NF, Weil RJ, Schroeder JL, Lang FF, Suki D, Sawaya RE (2014) Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol 32:774–782.  https://doi.org/10.1200/JCO.2013.51.8886 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Iorgulescu B (2017) OS04.3 extent of resection and overall survival in risk adjusted and exact matched analyses of 22,928 glioblastoma (all molecular subtypes) patients. Neuro-oncology.  https://doi.org/10.1093/neuonc/nox036.023 CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Esquenazi Y, Friedman E, Liu Z, Zhu JJ, Hsu S, Tandon N (2017) The survival advantage of “supratotal” resection of glioblastoma using selective cortical mapping and the subpial technique. Neurosurgery.  https://doi.org/10.1093/neuros/nyw174 CrossRefPubMedGoogle Scholar
  21. 21.
    Yan JL, van der Hoorn A, Larkin TJ, Boonzaier NR, Matys T, Price SJ (2017) Extent of resection of peritumoral diffusion tensor imaging-detected abnormality as a predictor of survival in adult glioblastoma patients. J Neurosurg 126:234–241.  https://doi.org/10.3171/2016.1.JNS152153 CrossRefPubMedGoogle Scholar
  22. 22.
    Pessina F, Navarria P (2017) OS04.4 supratotal resection in newly diagnosed glioblastoma: role of this surgical strategy beyond contrast enhancing boundaries. Neuro-oncology 19:iii7-iii8.  https://doi.org/10.1093/neuonc/nox036.024 CrossRefPubMedCentralGoogle Scholar
  23. 23.
    Hrabalek L, Kalita O, Vaverka M, Zlevorova M, Ehrmann J Jr, Cechakova E, Adamus M, Novak V, Langova K (2015) Resection versus biopsy of glioblastomas in eloquent brain areas. Biomed Pap 159:150–155.  https://doi.org/10.5507/bp.2013.052 CrossRefGoogle Scholar
  24. 24.
    Zhang J, Chen X, Zhao Y, Wang F, Li F, Xu B (2014) Impact of intraoperative magnetic resonance imaging and functional neuronavigation on surgical outcome in patients with gliomas involving language areas. Neurosurg Rev.  https://doi.org/10.1007/s10143-014-0585-z CrossRefPubMedGoogle Scholar
  25. 25.
    Hassaneen W, Levine NB, Suki D, Salaskar AL, de Moura Lima A, McCutcheon IE, Prabhu SS, Lang FF, DeMonte F, Rao G, Weinberg JS, Wildrick DM, Aldape KD, Sawaya R (2011) Multiple craniotomies in the management of multifocal and multicentric glioblastoma. Clinical article. J Neurosurg 114:576–584.  https://doi.org/10.3171/2010.6.JNS091326 CrossRefPubMedGoogle Scholar
  26. 26.
    Kreth FW, Thon N, Simon M, Westphal M, Schackert G, Nikkhah G, Hentschel B, Reifenberger G, Pietsch T, Weller M, Tonn JC, German Glioma N (2013) Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol 24:3117–3123.  https://doi.org/10.1093/annonc/mdt388 CrossRefPubMedGoogle Scholar
  27. 27.
    Chaichana KL, Garzon-Muvdi T, Parker S, Weingart JD, Olivi A, Bennett R, Brem H, Quinones-Hinojosa A (2011) Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol 18:239–245.  https://doi.org/10.1245/s10434-010-1242-6 CrossRefPubMedGoogle Scholar
  28. 28.
    Oszvald A, Guresir E, Setzer M, Vatter H, Senft C, Seifert V, Franz K (2012) Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age. J Neurosurg 116:357–364.  https://doi.org/10.3171/2011.8.JNS102114 CrossRefPubMedGoogle Scholar
  29. 29.
    Uzuka T, Aoki H, Natsumeda M, Takahashi H, Fujii Y (2012) Effectiveness of maximal safe resection for glioblastoma including elderly and low Karnofsky performance status patients: retrospective review at a single institute. Neurol Medico-chirurgica 52:570–576CrossRefGoogle Scholar
  30. 30.
    Shinoda J, Sakai N, Murase S, Yano H, Matsuhisa T, Funakoshi T (2001) Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection. J Neurooncol 52:161–171CrossRefGoogle Scholar
  31. 31.
    Marcus HJ, Williams S, Hughes-Hallett A, Camp SJ, Nandi D, Thorne L (2017) Predicting surgical outcome in patients with glioblastoma multiforme using pre-operative magnetic resonance imaging: development and preliminary validation of a grading system. Neurosurg Rev.  https://doi.org/10.1007/s10143-017-0817-0 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T, Group AL-GS. (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62:564–576.  https://doi.org/10.1227/01.neu.0000317304.31579.17 (discussion 564–576)CrossRefPubMedGoogle Scholar
  33. 33.
    Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, Lillehei KO, Bernstein M, Brem H, Sloan A, Berger MS, Chang S, Glioma Outcomes I (2003) Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 99:467–473.  https://doi.org/10.3171/jns.2003.99.3.0467 CrossRefPubMedGoogle Scholar
  34. 34.
    Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A (2010) AJCC cancer staging manual, 7th edn. Springer, New York, NYGoogle Scholar
  35. 35.
    Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefGoogle Scholar
  36. 36.
    Chaichana K, Parker S, Olivi A, Quinones-Hinojosa A (2010) A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme. J Neurosurg 112:997–1004.  https://doi.org/10.3171/2009.9.JNS09805 CrossRefPubMedGoogle Scholar
  37. 37.
    Shinoda J, Yano H, Yoshimura S, Okumura A, Kaku Y, Iwama T, Sakai N (2003) Fluorescence-guided resection of glioblastoma multiforme by using high-dose fluorescein sodium. Technical note. J Neurosurg 99:597–603.  https://doi.org/10.3171/jns.2003.99.3.0597 CrossRefPubMedGoogle Scholar
  38. 38.
    Qin JJ, Liu ZX, Wang JM, Du J, Xu L, Zeng C, Han W, Li ZD, Xie J, Li GL (2015) Prognostic factors influencing clinical outcomes of malignant glioblastoma multiforme: clinical, immunophenotypic, and fluorescence in situ hybridization findings for 1p19q in 816 chinese cases. Asian Pac J Cancer Prev 16:971–977CrossRefGoogle Scholar
  39. 39.
    Keles GE, Anderson B, Berger MS (1999) The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 52:371–379CrossRefGoogle Scholar
  40. 40.
    McGirt MJ, Mukherjee D, Chaichana KL, Than KD, Weingart JD, Quinones-Hinojosa A (2009) Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery 65:463–469.  https://doi.org/10.1227/01.NEU.0000349763.42238.E900006123-200909000-00013 (discussion 469–470)CrossRefPubMedGoogle Scholar
  41. 41.
    Jakola AS, Gulati S, Weber C, Unsgard G, Solheim O (2011) Postoperative deterioration in health related quality of life as predictor for survival in patients with glioblastoma: a prospective study. PLoS ONE 6:e28592.  https://doi.org/10.1371/journal.pone.0028592PONE-D-11-13796 CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Senft C, Forster MT, Bink A, Mittelbronn M, Franz K, Seifert V, Szelenyi A (2012) Optimizing the extent of resection in eloquently located gliomas by combining intraoperative MRI guidance with intraoperative neurophysiological monitoring. J Neurooncol 109:81–90.  https://doi.org/10.1007/s11060-012-0864-x CrossRefPubMedGoogle Scholar
  43. 43.
    Schucht P, Murek M, Jilch A, Seidel K, Hewer E, Wiest R, Raabe A, Beck J (2013) Early re-do surgery for glioblastoma is a feasible and safe strategy to achieve complete resection of enhancing tumor. PLoS ONE 8:e79846.  https://doi.org/10.1371/journal.pone.0079846 CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    D’Amico RS, Englander ZK, Canoll P, Bruce JN (2017) Extent of resection in glioma—a review of the cutting edge. World Neurosurg.  https://doi.org/10.1016/j.wneu.2017.04.041 CrossRefPubMedGoogle Scholar
  45. 45.
    Kubben PL, ter Meulen KJ, Schijns OE, ter Laak-Poort MP, van Overbeeke JJ, van Santbrink H (2011) Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. Lancet Oncol 12:1062–1070CrossRefGoogle Scholar
  46. 46.
    Li P, Qian R, Niu C, Fu X (2017) Impact of intraoperative MRI-guided resection on resection and survival in patient with gliomas: a meta-analysis. Curr Med Res Opin 33:621–630.  https://doi.org/10.1080/03007995.2016.1275935 CrossRefPubMedGoogle Scholar
  47. 47.
    Napolitano M, Vaz G, Lawson TM, Docquier MA, van Maanen A, Duprez T, Raftopoulos C (2014) Glioblastoma surgery with and without intraoperative MRI at 3.0T. Neurochirurgie 60:143–150.  https://doi.org/10.1016/j.neuchi.2014.03.010 CrossRefPubMedGoogle Scholar
  48. 48.
    Roder C, Bisdas S, Ebner FH, Honegger J, Naegele T, Ernemann U, Tatagiba M (2014) Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery. Eur J Surg Oncol 40:297–304.  https://doi.org/10.1016/j.ejso.2013.11.022 CrossRefPubMedGoogle Scholar
  49. 49.
    Engelen MJ, Kos HE, Willemse PH, Aalders JG, de Vries EG, Schaapveld M, Otter R, van der Zee AG (2006) Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 106:589–598.  https://doi.org/10.1002/cncr.21616 CrossRefPubMedGoogle Scholar
  50. 50.
    Khan UA, Bhavsar A, Asif H, Karabatsou K, Leggate JR, Sofat A, Kamaly-Asl ID (2015) Treatment by specialist surgical neurooncologists improves survival times for patients with malignant glioma. J Neurosurg 122:297–302.  https://doi.org/10.3171/2014.10.JNS132057 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  • Jaume Capellades
    • 1
  • Josep Puig
    • 2
  • Sira Domenech
    • 3
  • Teresa Pujol
    • 4
  • Laura Oleaga
    • 4
  • Angels Camins
    • 5
  • Carles Majós
    • 5
  • Rocio Diaz
    • 3
  • Christian de Quintana
    • 6
  • Pilar Teixidor
    • 7
  • Gerard Conesa
    • 8
  • Gerard Plans
    • 9
  • Josep Gonzalez
    • 10
  • Natalia García-Balañà
    • 11
  • Jose Maria Velarde
    • 11
  • Carmen Balaña
    • 12
    Email author return OK on get
  1. 1.Radiology Hospital del MarBarcelonaSpain
  2. 2.Imaging Research Unit, Institut Diagnòstic per la Imatge (IDI), Biomedical Research Institute (IDIBGI)Hospital Universitari Dr Josep TruetaGironaSpain
  3. 3.RadiologyInstitut Diagnòstic per la Imatge (IDI)BadalonaSpain
  4. 4.Radiology DepartmentHospital ClinicBarcelonaSpain
  5. 5.RadiologyInstitut Diagnòstic per la Imatge (IDI)L’Hospitalet de LLobregatSpain
  6. 6.Neurosurgery DepartmentHospital de la Santa Creu i de Sant PauBarcelonaSpain
  7. 7.Neurosurgery DepartmentHospital Germans Trias I PujolBadalonaSpain
  8. 8.Neurosurgery DepartmentHospital del MarBarcelonaSpain
  9. 9.Neurosurgery DepartmentHospital de BellvitgeL’Hospitalet de LLobregatSpain
  10. 10.Neurosurgery DepartmentHospital ClinicBarcelonaSpain
  11. 11.Institut Investigació Germans Trias i Pujol (IGTP)BadalonaSpain
  12. 12.Medical Oncology Service, Institut Català d’Oncologia (ICO)Hospital Germans Trias i PujolBarcelonaSpain

Personalised recommendations